VolitionRx published a preprint describing a ChIP‑seq‑based liquid biopsy method, Capture‑Seq, that isolates cell‑free DNA fragments bound to CTCF protein (cfCTCF‑DNA) from plasma to identify cancer‑specific CTCF binding site occupancy. The company reports dramatic signal enrichment and claims the approach reduces background noise versus standard cfDNA assays. Authors showed a reported 180‑fold increase in CTCF‑associated fragment proportion after capture and used bioinformatics to identify differentially occupied sites between cancer patients and controls. VolitionRx is validating findings and seeking licensing partners for further development. If reproducible, cfCTCF profiling adds a novel epigenetic biomarker class to the liquid biopsy toolkit, with potential to improve early detection and tumor‑of‑origin signals. Independent validation, prospective cohorts, and clinical utility studies will determine adoption by diagnostics players.